The abstract is read at the publisher; the summary is JClub's.
PABPC1 upregulation in therapy-resistant prostate cancer is linked to enzalutamide resistance by suppressing tumor ferroptosis and CD8+ T-cell cytotoxicity.
- Why it matters: Resistance to next-generation androgen receptor antagonists is a major clinical challenge, and the mechanisms connecting RNA regulation to metabolic and immune reprogramming remain unclear.
- What they did: Using integrated analysis across multiple cohorts, the study tested how PABPC1 controls EIF4A1–ATF4 mRNA translation, ATF4-driven BCAT1 transcription, and BCAA remodeling, then evaluated ixazomib plus Enz in preclinical models.
- The result: The PABPC1–ATF4–BCAT1 axis is implicated in treatment resistance, and ixazomib restored ferroptotic vulnerability, reinvigorated T-cell activity, and synergized with Enz without overt major-organ histopathological abnormalities.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.